Vascular Biogenics Ltd. Announces $24 Million Registered Direct Offering
07 juin 2016 07h44 HE
|
VBL Therapeutics
TEL AVIV, Israel, June 07, 2016 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ:VBLT), today announced that it has agreed to the sale and issuance of...
VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer
06 juin 2016 07h00 HE
|
VBL Therapeutics
VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose level (810 days vs. 172 days, p=0.042)60% (9 of 15) durable response rate (as measured by...
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data
03 juin 2016 16h02 HE
|
VBL Therapeutics
VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...
VBL Therapeutics Announces First Quarter 2016 Financial Results and Provides Business Update
13 mai 2016 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 13, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Report First Quarter 2016 Financial Results on May 13
05 mai 2016 16h02 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...
VBL Therapeutics Announces Clinical Data to be Presented at 2016 ASCO Annual Meeting
03 mai 2016 11h02 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 03, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Host Key Opinion Leader Meeting on Wednesday, May 4 in New York City
27 avr. 2016 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, April 27, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Publication of NASH Data for Lecinoxoids Molecules VB-201 and VB-703
19 avr. 2016 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, April 19, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Full-Year 2015 Financial Results and Provides Business Update
29 mars 2016 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, March 29, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Report Fourth Quarter & Fiscal Year 2015 Financial Results on March 29
07 mars 2016 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, March 07, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...